Colorectal Cancer Precision Medicine Clara Montagut

Solé L, Lobo T, Cabré J, Gonzalez A, Fernández-Ibarrondo L, Marruecos L, Guix M, Cuatrecasas M, Lopez S, Bellosillo B, Torres F, Iglesias M, Bigas A, Espinosa L^*. Loss of the epithelial marker CDX1 predicts poor prognosis in early-stage CRC patients. BBA-Mol Cell Res 2024; 1871(3): 119658.
Santana-Hernández S, Suárez J, Servitja S, Berenguer-Molins P, Costa-Garcia M, Comerma L, Rea A, Perera J, Menéndez S, Arpí O, Bermejo B, Martínez-Larrad MT, Cejalvo JM, Comino-Méndez I, Pascual J, Alba E, López-Botet M, Rojo F, Rovira A, Albanell J, Muntasell A^*. NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer. J Exp Clin Canc Res 2024; 43(1): 10.

Coordinator:
Clara Montagut(ELIMINAR)

Tel:
93 316 04 35

Pg Marítim, 25-29
08003 Barcelona